
VALOR Biogen’s Tofersen trial: a look at the open label extension data
Reading Time: 6 minutes The Motor Neurone Disease Association are pleased to discuss the additional results from the Biogen phase 3 clinical trial of Tofersen which were presented at the 20th European Network for the Cure of Amyotrophic Lateral Sclerosis (ENCALS) meeting in Edinburgh, Scotland, on the 1-3rd of June 2022. Tofersen is a type of potential treatment known…